Anidulafungine : une nouvelle option thérapeutique dans les candidoses systémiques

Marchetti, 2004, Epidemiology of candidemia in Swiss tertiary care hospitals: secular trends, 1991–2000, Clin Infect Dis, 38, 311, 10.1086/380637 Edmond, 1999, Nosocomial bloodstream infections in United States hospitals: a three-year analysis, Clin Infect Dis, 29, 239, 10.1086/520192 Tortorano, 2004, Epidemiology of candidaemia in Europe: results of 28-month European Confederation of Medical Mycology (ECMM) hospital-based surveillance study, Eur J Clin Microbiol Infect Dis, 23, 317, 10.1007/s10096-004-1103-y Almirante, 2005, Epidemiology and predictors of mortality in cases of Candida bloodstream infection: results from population-based surveillance, Barcelona, Spain, from 2002 to 2003, J Clin Microbiol, 43, 1829, 10.1128/JCM.43.4.1829-1835.2005 Lortholary, 2007, In vitro susceptibility to posaconazole of 1,903 yeast isolates recovered in France from 2003 to 2006 and tested by the method of the European Committee on Antimicrobial Susceptibility Testing, Antimicrob Agents Chemother, 51, 3378, 10.1128/AAC.00496-07 Pfaller, 2007, Use of fluconazole as a surrogate marker to predict susceptibility and resistance to voriconazole among 13,338 clinical isolates of Candida spp. tested by Clinical and Laboratory Standards Institute-recommended broth microdilution methods, J Clin Microbiol, 45, 70, 10.1128/JCM.01551-06 Vazquez, 2006, Anidulafungin: a novel echinocandin, Clin Infect Dis, 43, 215, 10.1086/505204 De la Torre, 2007, Anidulafungin: a new echinocandin for candidal infections, Expert Rev Anti Infect Ther, 5, 45, 10.1586/14787210.5.1.45 Pfaller, 2005, In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole, J Clin Microbiol, 43, 5425, 10.1128/JCM.43.11.5425-5427.2005 Ostrosky-Zeichner, 2003, Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States, Antimicrob Agents Chemother, 47, 3149, 10.1128/AAC.47.10.3149-3154.2003 Karlowsky, 1997, In vitro kill curves of a new semisynthetic echinocandin, LY-303366, against fluconazole-sensitive and -resistant Candida species, Antimicrob Agents Chemother, 41, 2576, 10.1128/AAC.41.11.2576 Pfaller, 2004, Anidulafungin: an echinocandin antifungal, Expert Opin Investig Drugs, 13, 1183, 10.1517/13543784.13.9.1183 Petraitiene, 1999, Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits, Antimicrob Agents Chemother, 43, 2148, 10.1128/AAC.43.9.2148 Petraitis, 2001, Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis, Antimicrob Agents Chemother, 45, 471, 10.1128/AAC.45.2.471-479.2001 Dowell, 2004, Population pharmacokinetic analysis of anidulafungin, an echinocandin antifungal, J Clin Pharmacol, 44, 590, 10.1177/0091270004265644 Kim, 2007, A comparative evaluation of properties and clinical efficacy of the echinocandins, Expert Opin Pharmacother, 8, 1479, 10.1517/14656566.8.10.1479 Dowell, 2007, Anidulafungin does not require dosage adjustment in subjects with varying degrees of hepatic or renal impairment, J Clin Pharmacol, 47, 461, 10.1177/0091270006297227 Vazquez, 2005, Anidulafungin: a new echinocandin with a novel profile, Clin Ther, 27, 657, 10.1016/j.clinthera.2005.06.010 Dowell, 2005, Safety and pharmacokinetics of coadministered voriconazole and anidulafungin, J Clin Pharmacol, 45, 1373, 10.1177/0091270005281234 Dowell, 2005, Assessment of the safety and pharmacokinetics of anidulafungin when administered with cyclosporine, J Clin Pharmacol, 45, 227, 10.1177/0091270004270146 Dowell, 2007, Lack of pharmacokinetic interaction between anidulafungin and tacrolimus, J Clin Pharmacol, 47, 305, 10.1177/0091270006296764 Krause, 2004, Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia, Antimicrob Agents Chemother, 48, 2021, 10.1128/AAC.48.6.2021-2024.2004 Reboli, 2007, Anidulafungin versus fluconazole for invasive candidiasis, N Engl J Med, 356, 2472, 10.1056/NEJMoa066906 Krause, 2004, A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of oesophageal candidiasis, Clin Infect Dis, 39, 770, 10.1086/423378 European Public Assessment Report (EPAR) Ecalta. http://www.emea.europa.eu/humandocs/Humans/EPAR/ecalta/ecalta.htm.